Antigens Patents (Class 435/69.3)
-
Publication number: 20130318648Abstract: A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: (a) contacting a sample from the host with an agent selected from (i) the epitope comprising sequence which is: SEQ ID NO: 1 or 2, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, (ii) an epitope comprising sequence comprising: SEQ ID NO: 1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, which epitope is an isolated oligopeptide derived from a gliadin protein, (iii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50 amino acids in length, or (iv) a product comprising two or more agents as defined in (i), (ii) or (iii), and (b) determining in vitro whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is suType: ApplicationFiled: November 8, 2012Publication date: November 28, 2013Applicant: ISIS INNOVATION LIMITEDInventors: ROBERT PAUL ANDERSON, ADRIAN VIVIAN HILL, DEREK PARRY JEWELL
-
Publication number: 20130295609Abstract: A plant expression system and methods for expressing a protein of interest in a plant are provided. The plant expression system comprises a first nucleic acid sequence regulatory region sequence, operatively linked with a one or more than one comovirus enhancer, a nucleotide sequence of interest, one or more than one geminivirus amplification elements, and a second nucleic acid encoding a geminivirus replicase. The method of producing a protein of interest in a plant, involves introducing the plant expression system into a plant, or portion of the plant, and incubating the plant or the portion of the plant under conditions that permit the expression of the nucleotide sequence and producing the protein of interest.Type: ApplicationFiled: November 3, 2011Publication date: November 7, 2013Applicant: MEDICAGO INC.Inventors: Marc-Andre D'Aoust, Pierre-Olivier Lavoie, Louis-Philippe Vezina
-
Publication number: 20130295162Abstract: The disclosure provides a tetravalent Dengue virus vaccine, and methods of inducing a immune response against a Flavivirus such as Dengue virus 1-4 using the vaccine. The disclosure also provides methods of making a vaccine by introducing into a host cell a transgene that encodes a protein comprising Dengue domain III polypeptides, or, by purified dill polypeptides specific for Dengue serotypes 1-4, Yellow Fever Virus, West Nile Virus, Japanese Encephalitis Virus, and Flaviviruses.Type: ApplicationFiled: October 3, 2011Publication date: November 7, 2013Applicant: UNIVERSITY OF ROCHESTERInventors: Jacob J. Schlesinger, Xia Jin, Robert C. Rose, Olivia K.T. Block, W.W. Shanaka I. Rodrigo
-
Publication number: 20130295610Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.Type: ApplicationFiled: May 22, 2013Publication date: November 7, 2013Inventors: Rajan George, Lorne Tyrrell, Antoine Noujaim, Dakun Wang, Allan Ma
-
Patent number: 8574584Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.Type: GrantFiled: January 20, 2012Date of Patent: November 5, 2013Assignee: University of Pittsburgh —of the Commonwealth System of Higher EducationInventors: Walter J. Storkus, Michael S. Klnch
-
SECRETION YIELD OF A PROTEIN OF INTEREST BY IN VIVO PROTEOLYTIC PROCESSING OF A MULTIMERIC PRECURSOR
Publication number: 20130273606Abstract: The invention relates to a nucleic acid molecule encoding a multimeric precursor which after transcription is specifically cleaved in vivo to form multiple copies of a protein of interest. The invention further relates to a cell comprising this nucleic acid molecule and a method for producing a protein of interest using this cell.Type: ApplicationFiled: April 18, 2013Publication date: October 17, 2013Inventors: Anna Cornelia Hendrika VAN HAUTUM, Arjo Lysander DE BOER, Jan Bastiaan BOUWSTRA, Peter Franciscus Theresius Maria VAN ASTEN -
Publication number: 20130266604Abstract: Described herein is a peptide, referred to as a GlycoTag peptide, that includes repeats of an N-linked glycosylation sequon that is naturally present in C. jejuni. The GlycoTag peptide can be in a purified and isolated form following expression of a construct encoding the GlycoTag peptide or it is, in whole or in part, a synthetic peptide. The GlycoTag peptide is typically used with glycans attached thereto. The GlycoTag peptide can be used alone or in combination with different proteins or peptides and can be incorporated into a chimeric protein or peptide for use in the development of antigen/antibody delivery systems, the preparation of vaccines, pharmaceuticals and diagnostic tests, and research into therapies for countering Campylobacter and other infections.Type: ApplicationFiled: September 2, 2011Publication date: October 10, 2013Inventors: Christine Szymanski, Harald Nothaft
-
Publication number: 20130251744Abstract: The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof.Type: ApplicationFiled: February 15, 2013Publication date: September 26, 2013Applicant: VLP THERAPEUTICS, LLCInventors: Ryuji UENO, Wataru AKAHATA
-
Patent number: 8541003Abstract: SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule in a mammalian cell, uses for such immunogens, antigens or epitopes and vectors, e.g., as an active component immunogenic, immunological or vaccine compositions, or to generate antibodies, such as monoclonal antibodies, and methods for making, and using such immunogens, antigens or epitopes, vectors, antibodies, including in methods for eliciting an immunological or immunogenic or vaccine response, as well as in assays or diagnostic kits or methods, are discussed, as well as a seamless fusion of sequences in a plasmid or vector, e.g., a sequence encoding a leader sequence and a sequence encoding a protein, epitope or immunogen or antigen.Type: GrantFiled: June 21, 2004Date of Patent: September 24, 2013Assignee: Protein Sciences CorporationInventors: D. Karl Anderson, Kathleen M. Holtz-Corris, Rick Chubet, Daniel Adams, Manon Cox
-
BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES
Publication number: 20130243767Abstract: A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, and its use a medicament for the treatment of allergies.Type: ApplicationFiled: March 8, 2013Publication date: September 19, 2013Inventor: Geert Mudde -
Publication number: 20130237689Abstract: The production of soluble HLA class II molecules, as well as methods of using the soluble HLA class II molecules so produced, are described herein.Type: ApplicationFiled: April 10, 2013Publication date: September 12, 2013Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMAInventors: William H. Hildebrand, Steven Cate
-
Publication number: 20130236469Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.Type: ApplicationFiled: May 25, 2011Publication date: September 12, 2013Applicant: Intervacc ABInventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Publication number: 20130230529Abstract: Described herein are isolated paramyxovirus, a morbillivirus (FmoPV), isolated nucleic acids encoding the genome of FmoPV, isolated amino acid sequences of FmoPV proteins, antibodies to FmoPV and its proteins, and uses thereof. In certain embodiments, the modified FmoPV is a feline morbillivirus. Also described herein is a recombinant FmoPV comprising a modified FmoPV gene or gene segments and the use of such a virus. The recombinant FmoPV may be used in the prevention and/or treatment of diseases related to FmoPV or as a delivery vector. Also described herein is a diagnostic assay for the FmoPV. In certain embodiments, the FmoPV causes kidney disease. In certain embodiments, the kidney disease is in felines. In certain embodiments, the kidney disease is tubulointerstitial nephritis (“TIN”). Also described herein is a quantitative assay for the detection of the FmoPV, natural or artificial variants, analogs, or derivatives thereof.Type: ApplicationFiled: January 22, 2013Publication date: September 5, 2013Applicant: The University of Hong KongInventors: Kwok-Yung Yuen, Patrick Chiu-Yat Woo, Susanna Kar-Pui Lau
-
Patent number: 8524868Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.Type: GrantFiled: November 9, 2009Date of Patent: September 3, 2013Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen UniversityInventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
-
Publication number: 20130224246Abstract: A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding; and various uses thereof.Type: ApplicationFiled: August 4, 2011Publication date: August 29, 2013Inventors: Heidi Drummer, Kathleen McCaffrey, Pantelis Poumbourios
-
Publication number: 20130224236Abstract: The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: ApplicationFiled: November 3, 2011Publication date: August 29, 2013Applicant: UNIVERSITY OF WASHINGTONInventors: David M. Koelle, Lichen Jing
-
Publication number: 20130216566Abstract: SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule in a mammalian cell, uses for such immunogens, antigens or epitopes and vectors, e.g., as an active component immunogenic, immunological or vaccine compositions, or to generate antibodies, such as monoclonal antibodies, and methods for making, and using such immunogens, antigens or epitopes, vectors, antibodies, including in methods for eliciting an immunological or immunogenic or vaccine response, as well as in assays or diagnostic kits or methods, are discussed, as well as a seamless fusion of sequences in a plasmid or vector, e.g., a sequence encoding a leader sequence and a sequence encoding a protein, epitope or immunogen or antigen.Type: ApplicationFiled: June 21, 2004Publication date: August 22, 2013Inventors: D. Karl Anderson, Kathleen M. Holtz-Corris, Rick Chubet, Daniel Adams, Manon Cox
-
Publication number: 20130216563Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.Type: ApplicationFiled: August 1, 2012Publication date: August 22, 2013Inventors: Neil Berinstein, James Tartaglia, John A. Tine, Philippe Moingeon, Thierry Boon-Falleur, Pierre Vander Bruggen
-
Patent number: 8513397Abstract: Plant viral vectors have great potential in rapid production of proteins, but no simple. Here a geminivirus-based system for high-yield and rapid production of oligomeric protein complexes, including virus-like particle (VLP) vaccines and monoclonal antibodies (mAbs) is described. In particular, a single vector that contains two non-competing replicons for transient expression in Nicotiana benthamiana leaves is described. The correct assembly of these subunit proteins into functional oligomeric structures (VLPs or full-size mAb) is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of this technology for producing multiple-subunit protein complexes.Type: GrantFiled: August 27, 2009Date of Patent: August 20, 2013Assignee: The Arizona Board of Regents for and on behalf of Arizona State UniversityInventors: Hugh S. Mason, Zhong Huang, Qiang Chen, Charles J. Arntzen, Shuo Yuan, Brooke Hjelm
-
Patent number: 8506964Abstract: A fusion protein comprising an antigenic fragment of apoB-100 and a suitable carrier and related compositions methods and systems.Type: GrantFiled: February 4, 2011Date of Patent: August 13, 2013Assignee: CardioVax, LLCInventors: Jan Nilsson, Goran K. Hansson, Jan Holmgren
-
Publication number: 20130202647Abstract: Disclosed herein are chloroplast transformation vectors constructed to enable expression and hyperaccumulation of membrane proteins in chloroplasts. Another embodiment relates to plants transformed with such vectors. Another embodiment relates to seeds and other plant tissues transformed with such vectors. Another embodiment relates to a method of increasing expression of membrane proteins in chloroplasts including transforming a plant cell with vectors described herein.Type: ApplicationFiled: December 17, 2012Publication date: August 8, 2013Applicant: University of Central Florida Research Foundation, Inc.Inventor: Henry Daniell
-
Publication number: 20130202627Abstract: Use of flagellins from the genus Marinobacter as vaccine adjuvants. This invention is based on the use of two recombinant flagellins, F and FR, from the species Marinobacter algicola (DG893T strain), as vaccine adjuvants capable of developing a specific immune response, against peptides or proteins fused to said flagellins, or administered unfused jointly with the flagellins. This invention also describes new combined vaccination strategies, based on the two Marinobacter algicola flagellins and the Salmonella typhimurium flagellin.Type: ApplicationFiled: February 2, 2010Publication date: August 8, 2013Applicant: INSTITUTO NACIONAL DE INVESTIGACIÓN Y TECNOLOGÍA AGRARIA Y ALIMENTARIA (INIA)Inventor: Eduardo Gómez Casado
-
Patent number: 8501926Abstract: The present invention features immunogenic compositions based on pre-fertilization or post-fertilization antigens expressed in the circulating gametocytes in the peripheral blood of infected persons or on the malaria parastes' stages of development in the mosquito midgut including extracellular male and female gametes, fertilized zygote and ookinete. The invention also features methods to prevent the transmission of malaria using the immunogenic compositions of the invention.Type: GrantFiled: July 22, 2009Date of Patent: August 6, 2013Assignees: The Johns Hopkins University, The United States of America, as represented by the Secretary of the ArmyInventors: Nirbhay Kumar, Evelina Angov
-
Publication number: 20130198897Abstract: The present invention is directed to targeting genes and genomes, modifying the activity of enzymes and protein expression in plants. In particular, the present invention relates to methods for reducing the activity of one or more endogenous glycosyltransferases such as N-acetylglucosaminyltransferase, ?(1,2)-xylosyltransferase and a(1,3)-fucosyl-transferase in a plant cell and to plants obtained by said method.Type: ApplicationFiled: March 22, 2011Publication date: August 1, 2013Applicant: PHILIP MORRIS PRODUCTS S.A.Inventors: Karen Keiko Oishi, Dionisius Elisabeth Antonius Florack, Prisca Campanoni, Carlo Massimo Pozzi, Jeremy Catinot, Nicolas Joseph Marie Sierro, Nikolai Valeryevitch Ivanov
-
Publication number: 20130189715Abstract: Disclosed is the cloning, expression and purification of a hemolysin protein and its protein fragments in Anaplasma phagocytophilum. The recombinant hemolysin and its protein fragments are useful in the ELISA detection of anaplasma pathogen. The use of same as a kit for ELISA is also disclosed.Type: ApplicationFiled: July 30, 2012Publication date: July 25, 2013Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLCInventors: John G. Hoey, Denise P. Dimitrov, Lisa P. Huang, Martin E. Adelson, Eli Mordechai
-
Publication number: 20130183341Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.Type: ApplicationFiled: January 4, 2013Publication date: July 18, 2013Applicant: MEDICAGO INC.Inventor: MEDICAGO INC.
-
Patent number: 8481332Abstract: A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.Type: GrantFiled: January 24, 2011Date of Patent: July 9, 2013Assignee: Stichting Voor de Technische WetenshappenInventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
-
Publication number: 20130171185Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.Type: ApplicationFiled: July 5, 2011Publication date: July 4, 2013Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
-
Publication number: 20130171182Abstract: The invention provides a protein comprising a first and a second copy of hepatitis B core antigen (HBcAg) in tandem, in which one or both of the copies of HBcAg comprises influenza virus A surface polypeptide M2 or a fragment thereof in the e1 loop.Type: ApplicationFiled: October 22, 2010Publication date: July 4, 2013Applicant: iQUR LimitedInventors: Michael Anthony Whelan, William Malcolm Rosenberg, Lucy Phillipa Beales
-
Publication number: 20130171140Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.Type: ApplicationFiled: June 24, 2011Publication date: July 4, 2013Applicant: VACCIBODY ASInventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
-
Publication number: 20130164313Abstract: The present invention relates to the provision of DNA sequences of group 4 major allergens from cereals. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.Type: ApplicationFiled: November 16, 2010Publication date: June 27, 2013Inventors: Andreas NANDY, Helmut Fiebig, Oliver Cromwell
-
Publication number: 20130164782Abstract: A method for the secretory production of a glycoprotein having a human-type sugar chain, comprising a step of introducing a gene of an enzyme capable of performing a transfer reaction of a galactose residue to a non-reducing terminal acetylglucosamine residue, and a gene of heterologous glycoprotein, to obtain a transformed plant cell, a step of culturing the plant cell, and a step of recovering the culture medium of the plant cell.Type: ApplicationFiled: September 14, 2012Publication date: June 27, 2013Applicant: Phyton Holdings, LLCInventors: Kazuhito FUJIYAMA, Tatsuji Seki
-
Patent number: 8470372Abstract: Provided is a fusion protein, which comprises human papillomavirus E7 antigen, virus capsid protein and molecular chaperone. Also provided is a macromolecule with immunogenicity aggregated by the fusion proteins. The particle morphology of the macromolecule is different from that of the virus-like particle. The macromolecule can be used for treatment of human papillomavirus relating diseases.Type: GrantFiled: June 18, 2008Date of Patent: June 25, 2013Assignees: Shanghai Zerun-Ankegens Biopharmaceutical Company, Ltd., Yunxu CAOInventor: Yunxu Cao
-
Publication number: 20130156805Abstract: The present invention regards polypeptides capable of eliciting an immunological response that is protective against Chlamydia trachomatis. The polypeptide comprises a first amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 2. Furthermore, production of these polypeptides and pharmaceutical compositions comprising them are also provided.Type: ApplicationFiled: May 27, 2011Publication date: June 20, 2013Applicant: SPIXIA BIOTECHNOLOGY ABInventors: Sören Andersson, Åke Strid
-
Publication number: 20130157310Abstract: The present invention includes a method to produce a recombinant mite Group 1 protein in a methyltrophic yeast or an Escherichia coli microorganism. The present invention also relates to a recombinant mite Group 1 protein obtained by such a method, such a recombinant protein being able to selectively bind IgE or cause proliferation of a T cell that proliferates in response to a native mite Group 1 protein. Also included in the present invention is the use of such a recombinant mite Group 1 protein to detect mite allergy or to reduce an allergic response to a mite Group 1 protein. The present invention also includes novel mite Group 1 nucleic acid molecules, proteins, recombinant molecules, and recombinant cells, as well as uses thereof.Type: ApplicationFiled: February 21, 2013Publication date: June 20, 2013Applicant: MERCK PATENT GMBHInventor: Merck Patent GmbH
-
Patent number: 8465945Abstract: The present invention includes a method to produce a recombinant mite Group 1 protein in a methyltrophic yeast or an Escherichia coli microorganism. The present invention also relates to a recombinant mite Group 1 protein obtained by such a method, such a recombinant protein being able to selectively bind IgE or cause proliferation of a T cell that proliferate in response to a native mite Group 1 protein. Also included in the present invention is the use of such a recombinant mite Group 1 protein to detect mite allergy or to reduce an allergic response to a mite Group 1 protein. The present invention also includes novel mite Group 1 nucleic acid molecules, proteins, recombinant molecules, and recombinant cells, as well as uses thereof.Type: GrantFiled: October 2, 2006Date of Patent: June 18, 2013Assignee: Merck Patent GmbHInventors: Elaine A. Best, Martin J. McDermott
-
Patent number: 8460674Abstract: The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: GrantFiled: February 8, 2010Date of Patent: June 11, 2013Assignee: University of WashingtonInventor: David M. Koelle
-
Patent number: 8455206Abstract: The gene associated and causative of classical late infantile neuronal ceroid lipofuscinosis (LINCL), CLN2, has been identified and characterized. The translation product of this gene is a novel protease and a deficiency in this activity results in LINCL. Identification of CLN2 will not only aid in the prevention of LINCL through genetic counseling but provides strategies and test systems for therapeutic intervention. In addition, further characterization of this previously unknown lysosomal enzyme may provide useful insights into other more common human neurodegenerative disorders. Finally, the utility of a general approach for determining the molecular bases for lysosomal disorders of unknown etiology has been demonstrated.Type: GrantFiled: December 23, 2011Date of Patent: June 4, 2013Assignee: University of Medicine and Dentistry of New JerseyInventors: Peter Lobel, David Sleat
-
Patent number: 8450087Abstract: The invention concerns a recombinant vector characterized in that it comprises a polynucleotide comprising a central initiation cis-active region (cPPT) and a termination cis-active region (CTS), the regions being of retroviral or retroviral-like origin, and the vector further comprising a predetermined nucleotide sequence (transgene or nucleotide sequence of interest) and retrotranscription regulating, expressing, and packaging signals of retroviral or retroviral-like origin.Type: GrantFiled: September 21, 2011Date of Patent: May 28, 2013Assignees: Institut Pasteur, Institut National de la Santé´ et de la Recherche Médicale, Centre National de la Recherche ScientifiqueInventors: Pierre Charneau, Véronique Zennou, Hüseyin Firat
-
Publication number: 20130129755Abstract: We describe a method of expressing a recombinant protein comprising mannose-terminated N-glycans from a host cell, the method comprising: (a) introducing a nucleic acid encoding a recombinant protein into a Chinese Hamster Ovary (CHO) cell comprising a mutation in the GnT 1 gene (GenBank Accession Number AF343963) leading to loss of GnT 1 function; and (c) expressing the recombinant protein from the host cell, in which the expressed recombinant protein comprises a mannose-terminated glycan structure, and in which the method does not include a step of introducing functional GnT-1 into the host cell. The method may be used for producing recombinant glucocerebrosidase with a mannose-terminated glycan structure, suitable for treatment or prevention of Gaucher's Disease.Type: ApplicationFiled: March 24, 2011Publication date: May 23, 2013Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventor: Zhiwei Song
-
Publication number: 20130129742Abstract: The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal.Type: ApplicationFiled: April 28, 2011Publication date: May 23, 2013Applicant: LEUKOLECT ASInventors: Bernt Th. Walther, Mirushe Miftari
-
Publication number: 20130129766Abstract: Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.Type: ApplicationFiled: November 1, 2012Publication date: May 23, 2013Inventors: Shirley LONGACRE, Hannah POLSON, Ronald PERRAUT, Faridabano NATO
-
Publication number: 20130129764Abstract: The invention relates to compositions and methods for the detection of various infectious organisms, including heartworm (Dirofilaria immitis), Ehrlichia Canis, Anaplasma phagocytophilum, and Borrelia burgdorferi. More particularly, this invention relates to antibodies that bind to a heartworm antigen, the E. Canis gp36 polypeptide, the A. phagocytophilum p44 polypeptide, the B. burgdorferi OspA, OspC, OspF, p39, p41 and VlsE polypeptides, and uses thereof.Type: ApplicationFiled: November 2, 2012Publication date: May 23, 2013Applicant: VCA Antech, Inc.Inventor: VCA Antech, Inc.
-
Publication number: 20130122034Abstract: The novel protein SA1789 from Staphylococcus aureus is provided as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Also provided is a composition, particularly a S. aureus vaccine, comprising SA1789 protein or a fragment or derivative thereof capable of generating an immune response that leads to the killing and clearance of S. aureus.Type: ApplicationFiled: July 8, 2011Publication date: May 16, 2013Inventors: Tessie B. McNeely, Hongxia Fan, Mark Andrew Miller
-
Publication number: 20130123467Abstract: The invention provides for methods and systems for engineering target proteins, based on protein sequence characteristics that influence the likelihood of obtaining a crystal suitable for X-ray structure solution, to improve protein crystallization, as well as related material.Type: ApplicationFiled: October 19, 2012Publication date: May 16, 2013Applicant: The Trustees of Columbia University in the City of New YorkInventor: The Trustees of Columbia University in the City of
-
Patent number: 8440427Abstract: A polynucleotide sequence is provided comprising a nucleic acid sequence encoding recombinant Protective Antigen (rPA). Also provided are expression vectors and host cells comprising the polynucleotide sequence of the invention, and methods for producing rPA.Type: GrantFiled: June 27, 2012Date of Patent: May 14, 2013Assignees: Health Protection Agency, Dynport Vaccine Company LLCInventors: John Brehm, Ian McEntee, Philip Vincent, Nigel Allison, Rossalyn Brehm, George Jack, Michael Herbert, Barbara T. Solow, Juan Arroyo, Randall K. Lapcevich
-
Publication number: 20130115234Abstract: The present invention provides a polynucleotide, polypeptide, recombinant modified vaccinia virus Ankara (rMVA) and related vaccine compositions and methods useful in the prevention and treatment of an influenza viral infection. Provided is an isolated polynucleotide encoding multiple copies of M2 influenza ectodomain peptides or rMVA comprising the polynucleotide. Also provided are methods for inducing an immune response to a subject against an influenza virus or for treating a disease or symptom caused by or resulting from infection with an influenza virus.Type: ApplicationFiled: March 28, 2011Publication date: May 9, 2013Applicant: Emergent Product Development Gaithersburg,Inc.Inventors: Tina Guina, Michael Lacy, Mario Skiadopoulos, Nutan Mytle
-
Publication number: 20130115219Abstract: The present invention provides an expression vector for cell-surface expression of proteins.Type: ApplicationFiled: February 28, 2011Publication date: May 9, 2013Applicant: F. Hoffmann-La Roche AGInventors: Jeremy Beauchamp, Anita Dreyer, Hugues Matile
-
Patent number: 8435522Abstract: Disclosed are humanized antibodies that bind specifically to the receptor CXCR3. The humanized antibodies may be antagonists and may be used to treat or diagnose conditions associated with CXCR3 function.Type: GrantFiled: January 29, 2008Date of Patent: May 7, 2013Assignee: Teva Biopharmaceuticals USA, Inc.Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke
-
Patent number: 8435760Abstract: The present invention relates to an expression system for the expression of proteins and peptides in a methanotrophic bacterium, preferably M. capsulatus. Further, the invention relates to the exportation and display of said peptides and proteins on the surface of said bacteria. The invention also describes a method for the production of a desired protein in M. capsulatus.Type: GrantFiled: September 19, 2008Date of Patent: May 7, 2013Assignee: Stiftelsen UniversitetsforskningInventors: Johan R. Lillehaug, Harald B. Jensen